Background Among breast cancers without human epidermal growth factor receptor 2 (HER2)
amplification, overexpression, or both, a large proportion express low levels of HER2 that …

Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …

Background An improvement in progression-free survival was shown with trastuzumab
deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast …

The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction
network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. …

Background Trastuzumab targets the extracellular domain of the HER2 protein. Adding
trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces …

Immune checkpoint regulators such as PD-L1 have become exciting new therapeutic targets
leading to long lasting remissions in patients with advanced malignancies. However, in …

Aim Real-life analysis of overall survival (OS) trends among metastatic breast cancer (MBC)
patients may help define medical needs and evaluate the impact of public health …

Cancer progression is driven in part by genomic alterations 1 . The genomic characterization
of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to …

BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and
are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-…

The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer
trials) aims to provide recommendations for definitions of TTE end points using a formal …